POSTER PAPERS

Poster 101
‘Direct selection of synthetic antibody fragments on cell surface targets from a phage-displayed library’
Amandeep K. Gakhal et al.
(University of Toronto, Toronto, Ontario, Canada)


Poster 102
‘Hydroponic plant culture for the production of a monoclonal antibody raised against MUC-1’
Luisa Madeira et al. (St George’s University of London, London, UK)


Poster 103
‘Non-classical binding of a polyreactive a-type anti-idiotypic antibody to B cells’
Cristina Mateo de Acosta et al.
(Center for Molecular Immunology, Havana, Cuba)


Poster 104
‘Anti-ricin neutralizing monoclonal antibodies’
Wei-Gang Hu et al.
(Defence Research & Development Canada, Medicine Hat, Alberta, Canada)


Poster 105
‘Tag-lite® is a powerful solution for the cellular screening and characterization of therapeutic antibodies targeting receptor tyrosine kinases’
Fabienne Charrier-Savournin et al.
(Cisbio Bioassays, Codolet, France)


Poster 106
‘A new cellular binding platform to measure the Fc gamma receptor (FcyR)/higG interaction based on the Tag-lite® technology’
Hamed Mokrane et al. (Cisbio Bioassays, Codolet, France)


Poster 107
‘MabLib: display and selection of large diversity antibody libraries in mammalian cells’
Christopher Bond
(OncoMed Pharmaceuticals Inc., Redwood City, California, USA)


Poster 108
‘B-cell hybridoma coculture within EL-4 thymoma cells enhances hybridoma cell growth and monoclonal antibody production’
Alicia Martin-Lopez et al. (University of Almeria, Almeria, Spain)


Poster 109
‘Effects of CD40 activation in B-cell hybridomas engineered to overexpress CD40: Clonal variation for proliferation and monoclonal antibody production’
Alicia Martin-Lopez et al. (University of Almeria, Almeria, Spain)


Poster 110
'RECRUIT-TandAbs - Engaging immune cells to kill cancer cells: AFM13 - A bispecific tetravalent TandAb for treating Hodgkin lymphoma'
E. Rajkovic et al. (Affimed Therapeutics AG, Heidelberg, Germany)


Poster 111
'Targeting the MUC1-SEA module with antibodies for ablating human MUC1 positive cancer cells'
Edward Pichinuk and Daniel H. Wreschner
(Tel-Aviv University, Ramat Aviv, Israel)